Test Pages

Tuesday, April 28, 2020

CSL Executive VEEP: Leaders lead during uncertainty - there is no question that we are all experiencing the impact of COVID-19

CSL Behring and Takeda Pharmaceutical Company Limited are leading a joint effort with Biotest, BPL Group, LFB, and Octapharm to develop a potential plasma-derived therapy for treating COVID-19. The alliance started immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19.


“Leaders lead during uncertainty. There is no question that we are all experiencing the impact of COVID-19,” said Bill Mezzanotte, CSL Behring’s Executive Vice President and Head of Research and Development.Read more from B. Mezzanote.

 Test